Pam Harrison

Intravenous calcium plus magnesium given before or after adjuvant FOLFOX chemotherapy has absolutely no effect on the development of sensory neurotoxicity induced by oxaliplatin.

A simple and inexpensive blood test is being developed that can be used to screen patients for premalignant colorectal cancer lesions which, once perfected, will be a real game changer.

Better responders within a cohort of patients from the VELOUR study derive enhanced benefit from aflibercept when combined with FOLFIRI, a post-hoc analysis of the study shows.

Ramucirumab significantly prolongs survival in patients with advanced gastric or gastroesophageal junction adenocarcinoma following progression on first-line therapy.

Treatment with weekly nab-paclitaxel plus gemcitabine remains a strong independent predictor of both OS and PFS in patients with metastatic pancreatic cancer compared with gemcitabine alone.

Patients who express low levels of a critical gene involved in transporting gemcitabine into pancreatic tumor cells have virtually no overall survival advantage from treatment with the drug in the adjuvant setting.